1B-LSD: Difference between revisions

Line 178:

Although no formal studies have been conducted, it is assumed that like LSD itself, 1B-LSD is [[Addiction potential::non-addictive with a low abuse potential]]. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.<ref>{{cite journal|last1=Nichols|first1=David E.|author-link=David E. Nichols|year=2004|title=Hallucinogens|journal=Pharmacology & Therapeutics|volume=101|issue=2|pages=131-181|doi=10.1016/j.pharmthera.2003.11.002|issn=0163-7258}}</ref> Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped.{{citation needed}} It is assumed that 1B-LSD shares these properties with LSD.

Tolerance to the effects of 1B-LSD ~~are~~ built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1B-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1B-LSD they will have a reduced effect.

Tolerance to the effects of 1B-LSD is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1B-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1B-LSD they will have a reduced effect.

===Dangerous interactions===

Line 196:

*'''Latvia''': 1B-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>

*'''Lithuania''': 1B-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since June 5, 2019.<ref>{{cite web|url=https://www.e-tar.lt/portal/lt/legalActEditions/TAR.7B3B40DCD13A|title=LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo|access-date=January 1, 2020|language=lt}}</ref>

*'''Singapore''': 1P-LSD is a Class A controlled substance.<ref>{{cite web|title=Misuse of Drugs Act: (CHAPTER 185)|url=https://sso.agc.gov.sg/Act/MDA1973|website=sso.agc.gov.sg|date=March 31, 2008|access-date=October 22, 2020}}</ref>

*'''Sweden''': Following its sale as a [[designer drug]], 1B-LSD was made illegal in Sweden on January 26, 2016.<ref>{{cite web|url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara|title=31 nya substanser klassas som narkotika eller hälsofarlig vara|publisher=Folkhälsomyndigheten [Public Health Agency of Sweden]|access-date=January 1, 2020|publication-date=January 26, 2016|language=sv}}</ref>

*'''Switzerland''': 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>

@@ Line 178: / Line 178: @@
 Although no formal studies have been conducted, it is assumed that like LSD itself, 1B-LSD is [[Addiction potential::non-addictive with a low abuse potential]]. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.<ref>{{cite journal|last1=Nichols|first1=David E.|author-link=David E. Nichols|year=2004|title=Hallucinogens|journal=Pharmacology & Therapeutics|volume=101|issue=2|pages=131-181|doi=10.1016/j.pharmthera.2003.11.002|issn=0163-7258}}</ref> Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped.{{citation needed}} It is assumed that 1B-LSD shares these properties with LSD.
-Tolerance to the effects of 1B-LSD are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1B-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1B-LSD they will have a reduced effect.
+Tolerance to the effects of 1B-LSD is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1B-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1B-LSD they will have a reduced effect.
 ===Dangerous interactions===
@@ Line 196: / Line 196: @@
 *'''Latvia''': 1B-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
 *'''Lithuania''': 1B-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since June 5, 2019.<ref>{{cite web|url=https://www.e-tar.lt/portal/lt/legalActEditions/TAR.7B3B40DCD13A|title=LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo|access-date=January 1, 2020|language=lt}}</ref>
 *'''Singapore''': 1P-LSD is a Class A controlled substance.<ref>{{cite web|title=Misuse of Drugs Act: (CHAPTER 185)|url=https://sso.agc.gov.sg/Act/MDA1973|website=sso.agc.gov.sg|date=March 31, 2008|access-date=October 22, 2020}}</ref>
 *'''Sweden''': Following its sale as a [[designer drug]], 1B-LSD was made illegal in Sweden on January 26, 2016.<ref>{{cite web|url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara|title=31 nya substanser klassas som narkotika eller hälsofarlig vara|publisher=Folkhälsomyndigheten [Public Health Agency of Sweden]|access-date=January 1, 2020|publication-date=January 26, 2016|language=sv}}</ref>
 *'''Switzerland''': 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>